UNSPSC 51113402: Azelaic acid

This classification denotes an anti-infective agent with the molecular formula C9H16O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F2VW3D43YT, chemically known as 1,9-nonanedioic acid but more generally known as azelaic acid, which bears US NIH Compound Identifier 2266. European Medicines Agency schedules Azelaic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05648MIG.

UNSPSC 51113402 Azelaic acid is a Commodity code covering pharmaceutical active ingredients and finished formulations used in state and local healthcare and pharmacy benefit programs. The Texas Health and Human Services Commission (HHS) issued a Request for Information in April 2026 to explore direct-to-manufacturer prescription fulfillment models that would bypass traditional pharmacy benefit managers and wholesalers, signaling state procurement interest in supply-chain optimization and cost management for pharmaceutical products including active pharmaceutical ingredients. State health and human services agencies appear to be the primary issuing bodies under this code, with procurement focused on establishing alternative contracting pathways for pharmaceutical sourcing.

Recent activity is concentrated in Texas. The HHS Commission's RFI (HHS0017013), posted April 3, 2026 with the same-day response deadline, sought vendor capabilities for direct contracting with self-insured state employee health plans and government agencies using negotiated net pricing without rebate structures. The RFI is exploratory in nature and precedes formal competitive procurement; no award value, budget range, or binding contract terms are specified at this stage. The state indicated intent to use vendor responses to inform a future Request for Proposal with detailed financial parameters and implementation timelines.